Studies have reported that mutant EGFR can activate the mitogen-activated protein kinase (MAPK) signaling pathway and intersect with the Akt pathway to induce non-small cell lung cancer (NSCLC) resistance to AZD929. Here, WNK2 is linked to non-small cell lung carcinoma.